Polynovo (ASX:PNV) Total Liabilities : A$28.16 Mil (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Polynovo Total Liabilities?

Polynovo's Total Liabilities for the quarter that ended in Dec. 2023 was A$28.16 Mil.

Polynovo's quarterly Total Liabilities increased from Dec. 2022 (A$26.34 Mil) to Jun. 2023 (A$27.24 Mil) and increased from Jun. 2023 (A$27.24 Mil) to Dec. 2023 (A$28.16 Mil).

Polynovo's annual Total Liabilities increased from Jun. 2021 (A$15.99 Mil) to Jun. 2022 (A$17.26 Mil) and increased from Jun. 2022 (A$17.26 Mil) to Jun. 2023 (A$27.24 Mil).

Polynovo Total Liabilities Historical Data

The historical data trend for Polynovo's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Polynovo Total Liabilities Chart

Polynovo Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

2.13

14.05

15.99

17.26

27.24

Polynovo Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															16.52	17.26	26.34	27.24	28.16

Polynovo Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Polynovo's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	12.667	+	(14.154	+	0.233
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.184)
	=	27.24

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	92.621	-	65.383
	=	27.24

Polynovo's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	14.031	+	(13.697	+	0.428
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	28.16

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	97.208	-	69.052
	=	28.16

Polynovo Total Liabilities Related Terms

Thank you for viewing the detailed overview of Polynovo's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Polynovo (ASX:PNV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Polynovo Ltd (ASX:PNV) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

CALZF:USA MFJ:Germany

Address

320 Lorimer Street, Unit 2, Port Melbourne, VIC, AUS, 3207

Website

https://www.polynovo.com

Polynovo earns most of its revenue from U.S. sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

Polynovo (ASX:PNV) Headlines

No Headlines